

Risk Score		
VARIABLE	ADVERSE FACTOR	RISK SCORE
<i>TP53</i> status	Deleted or mutated	4
<i>IGHV</i> mutational status	Unmutated	2
β_2 -microglobulin concentration	>3.5 mg/L	2
Clinical stage	Rai I–IV or Binet B–C	1
Age	>65 years	1
Implications of Risk Score		
RISK SCORE	RISK CLASSIFICATION	5-YEAR SURVIVAL (TRAINING SET DATA)
0–1	Low	93.2%
2–3	Intermediate	79.3%
4–6	High	63.3%
7–10	Very high	23.3%

Abbreviation: CLL, chronic lymphocytic leukemia.

■ CRITERIA FOR THE INITIATION OF THERAPY

Currently, a watchful waiting strategy is used for most patients with CLL, with therapy reserved for patients with symptomatic disease. This recommendation is based on multiple trials showing no survival advantage with earlier therapy, although this question continues to be a focus of active investigation.

With the exception of patients participating on early intervention studies in CLL, disease-related symptoms that require the initiation of therapy are outlined in **Table 107-5**. Except for the rare patient who presents with disease requiring urgent therapy, most times, these symptoms can be monitored over short periods to determine relatedness to CLL and need for therapy.

TABLE 107-5 Criteria for the Initiation of Therapy